Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension

Journal of Hypertension

Volumn 32, Issue 1, 2014, Pages 135-141

  Ezzahti, Mustafa ^a   Moelker, Adriaan ^a   Friesema, Edith C H ^a   Van Der Linde, Nicole A J ^a   Krestin, Gabriel P ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aldosterone; Blood pressure; Endothelin 1; Noradrenaline; Renal nerve ablation; Renin

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; LOOP DIURETIC AGENT; NEUROHORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PARACETAMOL; POTASSIUM SPARING DIURETIC AGENT; RENIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRAMADOL;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTOMATION; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CATECHOLAMINE BLOOD LEVEL; CATHETER ABLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART RATE; HUMAN; KIDNEY NERVE; LABORATORY TEST; MALE; MIDDLE AGED; NORADRENALIN BLOOD LEVEL; OSCILLOMETER; OSCILLOMETRY; PAIN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENAL NERVE ABLATION; RESISTANT HYPERTENSION; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESISTANT HYPERTENSION; YOUNG ADULT;

ADULT; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DENERVATION; DRUG RESISTANCE; ENDOTHELIN-1; HUMANS; HYPERTENSION; KIDNEY; MIDDLE AGED; RENIN;

EID: 84891545495     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283658ef7     Document Type: Article

References (35)

1. Freyberg RH, Peet MM. The effect on the kidney of bilateral splanchnicectomy in patients with hypertension. J Clin Invest 1937; 16:49-65
2. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. JAMA 1953; 152:1501-1504
3. Thompson JE, Smithwick RH. Surgical measures in hypertension. Geriatrics 1953; 8:611-619
4. Krum H. Optimising management of chronic heart failure. Lancet 2009; 374:1808-1809
5. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281
6. Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR, et al. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension 2013; 61:225-231
7. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study. Circulation 2011; 123:1940-1946
8. Symplicity HTNI. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911-917
9. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet 2010; 376:1903-1909
10. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58:559-565
11. DiBona GF, Esler M. Translational medicine: The antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298:R245-R253
12. Kopp UC, Jones SY, DiBona GF. Afferent renal denervation impairs baroreflex control of efferent renal sympathetic nerve activity. Am J Physiol Regul Integr Comp Physiol 2008; 295:R1882-R1890
13. Van Der Hoorn FA, Boomsma F, Man in 't Veld AJ, Schalekamp MA. Determination of catecholamines in human plasma by high-performance liquid chromatography: Comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr 1989; 487:17-28
14. Vase H, Mathiassen ON, Kaltoft A, Pedersen EB, Christensen KL, Buus NH, et al. Catheter-based renal denervation for treatment of resistant hypertension. Dan Med J 2012; 59:A4439
15. Zuern CS, Rizas KD, Eick C, Stoleriu C, Bunk L, Barthel P, et al. Effects of renal sympathetic denervation on 24-h blood pressure variability. Front Physiol 2012; 3:134
16. Trazzi S, Mutti E, Frattola A, Imholz B, Parati G, Mancia G. Reproducibility of noninvasive and intra-arterial blood pressure monitoring: Implications for studies on antihypertensive treatment. J Hypertens 1991; 9:115-119
17. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419
18. Jansen PM, Danser AH, Imholz BP, Van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009; 27:680-691
19. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930
20. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15:333-339
21. Danser AH, Van Kats JP, Admiraal PJ, Derkx FH, Lamers JM, Verdouw PD, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24:37-48
22. Gordon RD, Kuchel O, Liddle GW, Island DP. Role of the sympathetic nervous system in regulating renin and aldosterone production in man. J Clin Invest 1967; 46:599-605
23. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012; 59:331-338
24. Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M, et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv 2012; 5:758-765
25. Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J 2011; 19:319-323
26. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11:723-728
27. Ye S, Zhong H, Yanamadala S, Campese VM. Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension 2006; 48:309-315
28. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: Prospective case series. Hypertension 2012; 60: 1485-1490
29. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013; 61:457-464
30. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, et al. Divergent results using clinic and ambulatory blood pressures: Report of a darusentan-resistant hypertension trial. Hypertension 2010; 56:824-830
31. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57:772-779
32. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, doubleblind, placebo-controlled trial. Lancet 2009; 374:1423-1431
33. Mancia G, Omboni S, Parati G, Sega R, Trazzi S. Ambulatory blood pressure monitoring in the design of studies on antihypertensive drug efficacy. Am J Hypertens 1993; 6:233S-235S.
34. White WB, Giles T, Bakris GL, Neutel JM, Davidai G, Weber MA. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J 2006; 151:176-184
35. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: Ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012; 60: 596-606